Assignee
NGM BIOPHARMACEUTICALS INC
US·70 granted patents·40 pending applications·680 citations·filing 2012–2025
Top patents by PatentIndex Score
110 records- 0198US9751924B2Methods of using compositions comprising fusion variants of FGF19 polypeptides for reducing glucose levels in a subjectNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Sep 5, 2017·32 cites·113 claims
- 0298US9670260B2Compositions comprising fusion variants of FGF19 polypeptidesNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Jun 6, 2017·34 cites·28 claims
- 0398US9580483B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of diabetesNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Feb 28, 2017·36 cites·120 claims
- 0498US9089525B1Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subjectNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Jul 28, 2015·37 cites·91 claims
- 0597US9974833B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having pregnancy intrahepatic cholestasisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted May 22, 2018·19 cites·54 claims
- 0697US9895416B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having cholestasisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Feb 20, 2018·25 cites·54 claims
- 0797US9889177B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having primary sclerosing cholangitisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Feb 13, 2018·25 cites·54 claims
- 0897US9889178B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having nonalcoholic steatohepatitisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Feb 13, 2018·25 cites·54 claims
- 0997US9878008B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorptionNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Jan 30, 2018·26 cites·54 claims
- 1097US9878009B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Jan 30, 2018·25 cites·54 claims
- 1197US9290557B2Compositions comprising variants and fusions of FGF19 polypeptidesNGM BIOPHARMACEUTICALS INC·Filed 2013·Granted Mar 22, 2016·37 cites·63 claims
- 1297US9273107B2Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseasesNGM BIOPHARMACEUTICALS INC·Filed 2013·Granted Mar 1, 2016·36 cites·63 claims
- 1397US9161966B2GDF15 mutein polypeptidesNGM BIOPHARMACEUTICALS INC·Filed 2014·Granted Oct 20, 2015·29 cites·25 claims
- 1496US10456449B2Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseasesNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Oct 29, 2019·10 cites·63 claims
- 1596US10174119B2Binding proteins and methods of use thereofNGM BIOPHARMACEUTICALS INC·Filed 2017·Granted Jan 8, 2019·10 cites·43 claims
- 1696US9963494B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subjectNGM BIOPHARMACEUTICALS INC·Filed 2013·Granted May 8, 2018·19 cites·85 claims
- 1796US9827291B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Nov 28, 2017·16 cites·46 claims
- 1895US10434144B2Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disordersNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Oct 8, 2019·11 cites·9 claims
- 1995US10398758B2Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditionsNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Sep 3, 2019·9 cites·32 claims
- 2095US9920118B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Mar 20, 2018·19 cites·34 claims
- 2195US9738716B2Beta klotho binding proteins and methods of use thereofNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Aug 22, 2017·9 cites·6 claims
- 2294US10413590B2Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subjectNGM BIOPHARMACEUTICALS INC·Filed 2017·Granted Sep 17, 2019·10 cites·121 claims
- 2394US9925242B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitisNGM BIOPHARMACEUTICALS INC·Filed 2013·Granted Mar 27, 2018·25 cites·52 claims
- 2494US9834586B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Dec 5, 2017·18 cites·61 claims
- 2594US9550819B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2013·Granted Jan 24, 2017·22 cites·33 claims
- 2693US10195250B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2016·Granted Feb 5, 2019·12 cites·34 claims
- 2793US10093735B2Beta-klotho binding proteinsNGM BIOPHARMACEUTICALS INC·Filed 2017·Granted Oct 9, 2018·4 cites·15 claims
- 2892US10869909B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2018·Granted Dec 22, 2020·4 cites·34 claims
- 2992US10610568B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2017·Granted Apr 7, 2020·5 cites·37 claims
- 3092US9828415B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2014·Granted Nov 28, 2017·17 cites·46 claims
- 3191US10961315B2Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibodyNGM BIOPHARMACEUTICALS INC·Filed 2019·Granted Mar 30, 2021·5 cites·31 claims
- 3291US10517929B2Pharmaceutical compositions comprising FGF19 variantsNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Dec 31, 2019·9 cites·82 claims
- 3390US11358995B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2020·Granted Jun 14, 2022·2 cites·33 claims
- 3490US10323075B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2017·Granted Jun 18, 2019·8 cites·34 claims
- 3589US11530260B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2020·Granted Dec 20, 2022·2 cites·44 claims
- 3689US10744185B2Methods of using variants of FGF19 polypeptides for the treatment of pruritusNGM BIOPHARMACEUTICALS INC·Filed 2016·Granted Aug 18, 2020·7 cites·52 claims
- 3789US10744191B2Beta klotho-binding proteins and methods of use thereofNGM BIOPHARMACEUTICALS INC·Filed 2018·Granted Aug 18, 2020·3 cites·28 claims
- 3888US11136381B2Anti-C3 antibodiesNGM BIOPHARMACEUTICALS INC·Filed 2019·Granted Oct 5, 2021·3 cites·44 claims
- 3988US10800843B2Beta klotho-binding proteinsNGM BIOPHARMACEUTICALS INC·Filed 2016·Granted Oct 13, 2020·3 cites·14 claims
- 4088US10562965B2Compositions and methods of use for treating metabolic disordersNGM BIOPHARMACEUTICALS INC·Filed 2018·Granted Feb 18, 2020·5 cites·39 claims
- 4188US10369199B2Methods of using variants of FGF19 polypeptides for the treatment of cancerNGM BIOPHARMACEUTICALS INC·Filed 2014·Granted Aug 6, 2019·9 cites·25 claims
- 4288US2024050530A1Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Metabolic Disorders and DiseasesNGM BIOPHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4387US10975154B2Binding proteins and methods of use thereofNGM BIOPHARMACEUTICALS INC·Filed 2018·Granted Apr 13, 2021·2 cites·56 claims
- 4487US2025188174A1Binding proteins and methods of use thereofNGM BIOPHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4586US11802155B2ILT-binding agents and methods of use thereofNGM BIOPHARMACEUTICALS INC·Filed 2021·Granted Oct 31, 2023·1 cites·34 claims
- 4686US11596676B2Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereofNGM BIOPHARMACEUTICALS INC·Filed 2020·Granted Mar 7, 2023·1 cites·21 claims
- 4786US10995145B2Antibodies which bind human glucagon receptorNGM BIOPHARMACEUTICALS INC·Filed 2018·Granted May 4, 2021·2 cites·29 claims
- 4885US11667708B2Anti-human beta klotho antibody or binding fragment thereof and methods of their useNGM BIOPHARMACEUTICALS INC·Filed 2020·Granted Jun 6, 2023·1 cites·59 claims
- 4985US11241481B2Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseasesNGM BIOPHARMACEUTICALS INC·Filed 2019·Granted Feb 8, 2022·1 cites·16 claims
- 5085US10071139B2Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragmentNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Sep 11, 2018·3 cites·20 claims
Showing the top 50 of 110 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when NGM BIOPHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →